SFDA Strengthens Its Global Leadership in Drug Regulation with Launch of NADR Program for Rare Disease Drug Development

Reinforcing its position as a leading global regulatory authority, the Saudi Food and Drug Authority (SFDA) has launched the New Accelerator Program for Drugs in Rare Diseases (NADR), a specialized regulatory initiative designed to support the development of and access to medicines for rare diseases, empower researchers and developers, and advance healthcare innovation.

Operating within the SFDA’s regulatory framework, the NADR program aims to streamline the development, evaluation, and authorization of drugs for rare diseases. By providing scientific and regulatory incentives, the initiative helps accelerate patient access to critical treatments, further strengthening Saudi Arabia’s position among leading countries in supporting researchers and fostering innovative solutions that advance the healthcare system.

The SFDA states that the NADR designation targets drugs intended to prevent or treat a rare, life-threatening, or seriously debilitating disease, as defined by a prevalence of fewer than 5 in 10,000 persons in Saudi Arabia. Eligible criteria include either no satisfactory treatment exists in Saudi Arabia, or the product offers significant clinical benefit over currently available therapeutic options; and the product could be under active development at any stage or already authorized by any regulatory authority but not yet registered in Saudi Arabia.

The SFDA has emphasized that facilitating timely access to medicines for patients with rare diseases remains a key priority. The NADR program therefore provides a tailored package of regulatory incentives and support measures, including dedicated scientific and regulatory guidance; flexible and innovative approaches to the evaluation of clinical evidence that take into account the challenges associated with small patient populations; streamlined procedures for manufacturer site registration; and flexible requirements for periodic safety update reports, where appropriate.

The launch of the NADR program forms part of the SFDA’s broader mission to expand access to these drugs, provide comprehensive healthcare for patients in Saudi Arabia, and enhance overall quality of life in alignment with the objectives of Saudi Vision 2030.